SciMed Biotech Podcast with Abu Abraham

The Fight for Functional Vision and How Cloudbreak is Rewriting the Future of Ocular Drug Development

Dr. Abu Abraham has spent over two decades at the forefront of ophthalmic drug development—leading teams, pioneering gene therapies, and bringing transformative treatments from early discovery through global regulatory approvals. Now, as Chief Medical Officer at Cloudbreak Pharma, he's channeling that experience into a mission to rewrite the future of eye health.

In this episode, we sit down with Dr. Abraham to talk about Cloudbreak’s ambitious pipeline, including the first-ever drug candidate for pterygium and novel solutions for myopia progression, dry eye, and diabetic macular edema. Abu also shares lessons from leading clinical teams at Santen and Amgen, how he approaches first-in-class innovation, and why he believes accessibility and quality of life should be front and center in ocular drug development.